Author: Javier Fernandez-Diaz

18 Dec

Posted at 13:54h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Laminar Pharma, empresa co-fundadora del Cluster Biotecnológico y Biomédico de las Illes Balears (BIOIB), recibe el Premio Onda Cero Mallorca de Ciencia e Investigación por sus avances científicos en el campo biomédico, especialmente...

10 Dec

Posted at 13:58h in Press, Sin categoría

  [vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]-> Laminar Pharma was selected as one of the 8 best European projects in the Health Care space by a prestigious panel of 28 directives of pharmaceutical companies and Venture Capital Funds specialized...

15 May

Posted at 14:00h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]After obtaining all required regulatory authorizations in the UK for the clinical study MIN-001-1203, Laminar Pharma confirmed the activation of the first site in Sutton, Surrey (UK), which will be recruiting participants from today....

13 Mar

Posted at 14:02h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]2OHOA is a new class of lipid regulator, multi-target anticancer drug for tumors with sphingomyelin metabolism alterations. It activates sphingomyelin synthase (SMS), a new and powerful potential anticancer drug target, which results in a specific...

04 Mar

Posted at 14:07h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]In the semi final session of the European Venture Contest, held on the 24th of October in Aarhus (Denmark), Laminar Pharma was one of the 6 projects selected by a prestigious panel of...

02 Mar

Posted at 14:04h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued in September 2011 a positive opinion recommending orphan medicinal product (Orphan Drug, OD) designation for 2OHOA for the treatment of glioma. 2OHOA is a novel investigational...